Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.
Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.
New research provides further evidence that thrombolysis benefits select patients with acute ischemic stroke up to 24 hours after symptom onset.
Researchers continue to advance the science to determine best treatments for stroke. Based on an international study of 530 patients, researchers discovered that while the clot retrieval procedure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback